Begin typing your search above and press return to search.
Covaxin Neutralises the UK strain of Covid-19 effectively: Bharat Biotech
By: Tupaki Desk | 27 Jan 2021 1:45 PM GMT
The new variant of the Coronavirus that was detected in the United Kingdom earlier in 2020 has spread to many nations across the globe including India. Compared to the other variants, the UK strain is more dangerous and highly transmissible,
The UK strain named B117 virus or VUI2020/21 has entered India too, and according to the information, not less than 150 people have found infected with the new lineage of the respiratory disease.
The new strain entering India has raised serious doubts on whether the vaccines approved for the massive vaccination drive in India can effectively work against the UK lineage.
Following this, the Hyderabad-based biotechnology company Bharat Biotech took to microblogging site Twitter to say that their vaccine neutralises the UK variant of the Coronavirus.
In the tweet, Bharat Biotech shared a link of the outcomes of the research carried out by the scientists at the National Institute of Virology(NIV). The biotech firm said it effectively neutralises the UK variant.
The Covaxin dose developed by Bharat Biotech is facing criticism as the Drugs Controller General of India(DCGI) approved the vaccine for the vaccination drive without the completion of the final stage of the clinical trials.
The UK strain named B117 virus or VUI2020/21 has entered India too, and according to the information, not less than 150 people have found infected with the new lineage of the respiratory disease.
The new strain entering India has raised serious doubts on whether the vaccines approved for the massive vaccination drive in India can effectively work against the UK lineage.
Following this, the Hyderabad-based biotechnology company Bharat Biotech took to microblogging site Twitter to say that their vaccine neutralises the UK variant of the Coronavirus.
In the tweet, Bharat Biotech shared a link of the outcomes of the research carried out by the scientists at the National Institute of Virology(NIV). The biotech firm said it effectively neutralises the UK variant.
The Covaxin dose developed by Bharat Biotech is facing criticism as the Drugs Controller General of India(DCGI) approved the vaccine for the vaccination drive without the completion of the final stage of the clinical trials.
